Jesus A. Frias-Iniesta

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final report.

Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final report.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: December 23, 2025

Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) - final report.

Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) - final report.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: December 23, 2025

Corrigendum to: An account on the history of pharmacology in Spain [Pharmacol. Res. 202 (2024) 107104 Pages 1-11 https://doi.org/10.1016/j.phrs.2024.107104].

Corrigendum to: An account on the history of pharmacology in Spain [Pharmacol. Res. 202 (2024) 107104 Pages 1-11 https://doi.org/10.1016/j.phrs.2024.107104].

Journal: Pharmacological research

Published: May 31, 2024

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: March 27, 2024

Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial-POSCAL Study.

Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial-POSCAL Study.

Journal: Nutrients

Published: December 22, 2023

The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium.

The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium.

Journal: Vaccines

Published: October 18, 2023

Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1).

Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1).

Journal: Vaccine

Published: June 04, 2023

VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.

VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.

Journal: Vaccine

Published: December 07, 2022

Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit.

Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit.

Journal: JMIR public health and surveillance

Published: November 21, 2022

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.

Journal: Trials

Published: July 28, 2022

VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment.

VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment.

Journal: Vaccine

Published: February 24, 2022

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

Journal: Lancet (London, England)

Published: May 26, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026